Cargando…
Evaluating the performance of copula models in phase I-II clinical trials under model misspecification
BACKGROUND: Traditionally, phase I oncology trials are designed to determine the maximum tolerated dose (MTD), defined as the highest dose with an acceptable probability of dose limiting toxicities(DLT), of a new treatment via a dose escalation study. An alternate approach is to jointly model toxici...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234400/ https://www.ncbi.nlm.nih.gov/pubmed/24731155 http://dx.doi.org/10.1186/1471-2288-14-51 |